Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Provided By GlobeNewswire
Last update: Oct 2, 2025
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.
Read more at globenewswire.com
